Mark M. Moasser

10.1k total citations · 3 hit papers
113 papers, 7.4k citations indexed

About

Mark M. Moasser is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark M. Moasser has authored 113 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 42 papers in Molecular Biology and 39 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark M. Moasser's work include HER2/EGFR in Cancer Research (45 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Mark M. Moasser is often cited by papers focused on HER2/EGFR in Cancer Research (45 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Mark M. Moasser collaborates with scholars based in United States, Netherlands and Canada. Mark M. Moasser's co-authors include Matthew J. Wieduwilt, Neal Rosen, Natalia Sergina, Andrea Basso, Kevan M. Shokat, Byron Hann, Jimmy A. Blair, Donghui Wang, Dhara N. Amin and Marcia R. Campbell and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Mark M. Moasser

111 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

2007 886 citations Mark M. Moasser Oncogene profile →
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

2007 765 citations Natalia Sergina, Jimmy A. Blair et al. profile →
The epidermal growth factor receptor family: Biology driving targeted therapeutics

2008 576 citations Mark M. Moasser et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark M. Moasser United States	40	4.2k	3.6k	1.7k	1.6k	890	113	7.4k
Tona M. Gilmer United States	30	3.8k 0.9×	4.0k 1.1×	1.2k 0.7×	1.0k 0.6×	850 1.0×	60	6.8k
Joaquı́n Arribas Spain	47	5.0k 1.2×	4.6k 1.3×	1.1k 0.7×	2.4k 1.4×	1.5k 1.7×	129	9.0k
Suzanne F. Jones United States	42	4.1k 1.0×	3.6k 1.0×	1.8k 1.0×	827 0.5×	1.1k 1.3×	231	7.8k
Ron Bose United States	33	3.1k 0.7×	3.5k 1.0×	1.3k 0.7×	1.0k 0.6×	1.2k 1.4×	94	6.7k
Violeta Serra Spain	36	3.1k 0.7×	4.2k 1.1×	1.6k 0.9×	578 0.4×	1.0k 1.1×	92	7.5k
Stephen R. Wedge United Kingdom	39	2.6k 0.6×	3.6k 1.0×	1.6k 0.9×	784 0.5×	1.4k 1.6×	103	7.0k
Antonella De Luca Italy	38	3.4k 0.8×	3.6k 1.0×	1.7k 1.0×	666 0.4×	1.4k 1.6×	102	6.8k
Anderson J. Ryan United Kingdom	42	2.9k 0.7×	3.9k 1.1×	1.4k 0.8×	715 0.4×	1.5k 1.7×	159	7.4k
Geke A.P. Hospers Netherlands	45	3.9k 0.9×	2.1k 0.6×	1.5k 0.8×	1.4k 0.9×	1.1k 1.2×	282	7.4k
Ling‐Ming Tseng Taiwan	43	4.9k 1.2×	3.6k 1.0×	1.6k 0.9×	1.3k 0.8×	3.0k 3.4×	228	8.8k

Countries citing papers authored by Mark M. Moasser

Since Specialization

Citations

This map shows the geographic impact of Mark M. Moasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Moasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Moasser more than expected).

Fields of papers citing papers by Mark M. Moasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Moasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Moasser. The network helps show where Mark M. Moasser may publish in the future.

Co-authorship network of co-authors of Mark M. Moasser

This figure shows the co-authorship network connecting the top 25 collaborators of Mark M. Moasser. A scholar is included among the top collaborators of Mark M. Moasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark M. Moasser. Mark M. Moasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gümüşay, Özge, Laura A. Huppert, Mark Jesus M. Magbanua, et al.. (2023). A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Research and Treatment. 203(2). 197–204. 1 indexed citations

Tsang, Erica S., Rahul Aggarwal, Emily K. Bergsland, et al.. (2022). A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications. 2(7). 570–576. 6 indexed citations

Campbell, Marcia R., Ana Ruiz-Sáenz, Christopher Agnew, et al.. (2022). Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports. 38(5). 110291–110291. 15 indexed citations

Ruiz-Sáenz, Ana, Farima Zahedi, Courtney A. Dreyer, et al.. (2021). Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. Molecular Cancer Research. 19(6). 957–967. 9 indexed citations

Majumder, Avisek, Manbir Sandhu, Debarko Banerji, et al.. (2021). The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Scientific Reports. 11(1). 9091–9091. 35 indexed citations

Badr, Christian E., Ana Ruiz-Sáenz, Jeffrey Serrill, et al.. (2020). Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Biochemical Pharmacology. 183. 114317–114317. 18 indexed citations

Yang, Chen‐Yen, Linlin Wang, Shervin Afghani, et al.. (2020). Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. Journal of Investigative Dermatology. 141(2). 364–373. 19 indexed citations

Aziz, May H. Abdel, Lijun Liu, Mark M. Moasser, et al.. (2020). Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expression and Purification. 179. 105780–105780. 1 indexed citations

Terranova-Barberio, Manuela, Nela Pawłowska, Mallika Dhawan, et al.. (2020). Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nature Communications. 11(1). 3584–3584. 119 indexed citations

10.

Bartelink, Imke H., Rahul Aggarwal, Jim Leng, et al.. (2017). Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical Cancer Research. 23(21). 6400–6410. 58 indexed citations

11.

Campbell, Marcia R., Hui Zhang, Ana Ruiz-Sáenz, et al.. (2016). Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast Cancer Research and Treatment. 155(3). 431–440. 15 indexed citations

12.

Amin, Dhara N., Deepika Ahuja, Paul Yaswen, & Mark M. Moasser. (2015). A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Molecular Cancer Therapeutics. 14(12). 2805–2817. 4 indexed citations

13.

Spassov, Danislav S., Ching Hang Wong, Sunny Y. Wong, Jeremy F. Reiter, & Mark M. Moasser. (2012). Trask Loss Enhances Tumorigenic Growth by Liberating Integrin Signaling and Growth Factor Receptor Cross-Talk in Unanchored Cells. Cancer Research. 73(3). 1168–1179. 22 indexed citations

14.

Spassov, Danislav S., Ching Hang Wong, Natalia Sergina, et al.. (2010). Phosphorylation of Trask by Src Kinases Inhibits Integrin Clustering and Functions in Exclusion with Focal Adhesion Signaling. Molecular and Cellular Biology. 31(4). 766–782. 26 indexed citations

15.

Wong, Ching Hang, Frederick L. Baehner, Danislav S. Spassov, et al.. (2009). Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. Clinical Cancer Research. 15(7). 2311–2322. 40 indexed citations

16.

Arkin, Michelle R. & Mark M. Moasser. (2008). HER-2-directed, small-molecule antagonists.. PubMed. 9(12). 1264–76. 8 indexed citations

17.

Moasser, Mark M.. (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 26(45). 6469–6487. 886 indexed citations breakdown →

18.

Hurria, Arti, Carol L. Rosen, Clifford A. Hudis, et al.. (2006). Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study. Journal of the American Geriatrics Society. 54(6). 925–931. 199 indexed citations

19.

She, Qing‐Bai, David B. Solit, Andrea Basso, & Mark M. Moasser. (2003). Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.. PubMed. 9(12). 4340–6. 244 indexed citations

20.

Moasser, Mark M., Andrea Basso, Steven D. Averbuch, & Neal Rosen. (2001). The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.. PubMed. 61(19). 7184–8. 437 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact